Back to clinical trials listBreast cancer

EvoPAR-Breast01

A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer ().

Open at Paris since : 17/06/2025
Target : Adult
Phase : Phase III

Trial description

The primary objective of this trial is to determine whether the combination of saruparib and camizestrant allows patients to live longer without disease progression (progression-free survival, PFS) compared to other endocrine therapy plus CDK4/6 inhibitor combinations, as assessed by an independent review committee.

Url of the trial

Main investigator

DELPHINE LOIRAT

Médecin

Contact